Resource use and costs of newly diagnosed cancer initial medical care

European Journal of Oncology

Volumn 19, Issue 3, 2014, Pages 166-184

  Dagovic, Aleksandar ^a   Walstra, Klazien Matter ^c   Gutzwiller, Florian S ^c   Djordjevic, Natasa ^b   Rankovic, Ana ^d   Djordjevic, Gordana ^e   Kocic, Sanja ^e   Vasiljevic, Dragan ^e   Canovic, Predrag ^b   Kovacevic, Aleksandra ^f   Aleksandar, Djukic ^d   Dragojevic Simic, Viktorija ^f   Jakovljevic, Mihajlo B ^b   Schwenkglenks, Matthias ^c  

^a CLINICAL CENTER KRAGUJEVAC   (Serbia)

^b UNIVERSITY OF KRAGUJEVAC   (Serbia)

^c Institut für Pharmazeutische Medizin ECPM   (Switzerland)

^d University Clinical Center Kragujevac   (Serbia)

^e Institute of Public Health Kragujevac   (Serbia)

^f UNIVERSITY OF DEFENCE   (Serbia)

Author keywords

Cancer incidence and cost; Database; Newly diagnosed; Oncology; Resource use patterns; Retrospective; Serbia

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ANTIPROTOZOAL AGENT; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BONE CANCER; BRAIN CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CAUSE OF DEATH; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM CANCER; DRUG COST; EYE CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; ICD-10; LIP CANCER; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; MEDICAL CARE; MELANOMA; METASTASIS; MIDDLE AGED; MOUTH CANCER; OUTPATIENT CARE; PHARYNX CANCER; RESOURCE ALLOCATION; RESPIRATORY TRACT TUMOR; RETROSPECTIVE STUDY; SKIN CANCER; SOFT TISSUE CANCER; SURVIVAL TIME; TELERADIOTHERAPY; TERMINAL CARE; THYROID CANCER;

EID: 84942324092     PISSN: 11286598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. World Health Organization International Agency for Research on Cancer: World Cancer Report 2008. Lyon 2008
2. Uyl-de Groot CA. Economic evaluation of cancer therapies: More and better studies will lead to better choices in cancer care. Eur J Cancer 2006; 42 (17): 2862-6.
3. Rescigno P, Imbevaro S, Jirillo A. The economic crisis and cancer chemotherapy: the role of the oncologist. Tumori 2012; 98 (4): 532-3.
4. Tappenden P, Chilcott J, Brennan A, et al. Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework. Value Health 2012; 15 (8): 1127-36.
5. Sipetic S, Bjegovic-Mikanovic V, Vlajinac H, etal. The burden of disease preventable by risk factor reduction in Serbia. Vojnosanit Pregl 2013; 70 (5): 445-51.
6. Obradovic M, Mrhar A, Kos M. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. Eur J Public Health 2010; 20 (4): 415-21.
7. Todorova I, Baban A, Alexandrova-Karamanova A, et al. Inequalities in cervical cancer screening in Eastern Europe: perspectives from Bulgaria and Romania. Int J Public Health 2009; 54 (4): 222-32.
8. Chroust K, Finek J, Zemanek P, et al. Experience in data management of the clinical retrospective project in Czech and Slovak oncology centres (IKARUS Project). Klin Onkol 2009; 22 (4): 163-7.
9. Nanda A, Nossikov A, Prokhorskas R, et al. Health in the central and eastern countries of the WHO European Region: an overview. World Health Stat Q 1993; 46 (3): 15865.
10. Macioch T, Hermanowski T. The indirect costs of cancer- related absenteeism in the workplace in Poland. J Occup Environ Med 2011; 53 (12): 1472-7.
11. Kim SY, Kim SG, Park JH, et al. Costs of initial cancer care and its affecting factors. J Prev Med Public Health 2009; 42 (4): 243-50.
12. Chiesa F, Tradati N, Calabrese L, et al. Thyroid disease in northern Italian children born around the time of the Chernobyl nuclear accident. Ann Oncol 2004; 15 (12): 1842-6.
13. Papathanasiou K, Gianoulis C, Tolikas A, et al. Effect of depleted uranium weapons used in the Balkan war on the incidence of cervical intraepithelial neoplasia (CIN) and invasive cancer of the cervix in Greece. Clin Exp Obstet Gynecol 2005; 32 (1): 58-60.
14. Department for Prevention and Control of Noncommunicable Diseases. Cancer incidence and mortality in central Serbia, Report No. XII, Institute of public health of Serbia “Dr Milan Jovanovic Batut”. Available at: http://www.ba- tut.org.rs/download/publikacije/Registar%20za%20rak%20 u%20Centralnoj%20Srbiji%202010.pdf (2012). (Accessed 30 August 2013)
15. Jakovljevic M, Jovanovic M, Lazic Z, et al. Current efforts and proposals to reduce healthcare costs in Serbia. Ser J Exp Clin Res 2011; 12 (4): 161-3.
16. Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies-report of the ISPOR Task Force on Retrospective Databases. Value Health 2003; 6 (2): 90-7.
17. Jakovljevic MB. Resource allocation strategies in Southeastern European health policy. Eur J Health Econ 2013; 14 (2): 153-9.
18. Leblanc TW, Abernethy AP. Defining quality, disseminating evidence, and enforcing guidelines for cancer treatment. Virtual Mentor 2013; 15 (8): 713-7.
19. The Republic Fund of Health Insurance. Republic of Serbia. Available at http://www.eng.rfzo.rs (Accessed 30 August 2013)
20. Health Statistical Yearbook of Republic of Serbia 2011. Institute of Public Health of Serbia, Belgrade “Dr Milan Jovanovic Batut”. Available at: http://www.batut.org.rs/download/publikacije/pub2011.pdf(2012)
21. StatSoft Inc. Statistica. Version 8. Statsoft, Inc., Tulsa, Oklahoma, 2008.
22. Radovanovic A, Dagovic A, Jakovljevic M. Economics of cancer related medical care: estimates worldwide and available domestic evidence. Arch Oncol 2011; 19 (3-4): 59-63.
23. Biorac N, Jakovljevic M, Stefanovic D, et al. Assessment of diabetes mellitus type 2 treatment costs in the Republic of Serbia. Vojnosanit Pregl 2009; 66 (4): 271-6.
24. Jovanovic M, Jakovljevic M. Inpatient detoxification procedure and facilities: financing considerations from an Eastern European perspective. Alcohol Alcohol 2011; 46 (3): 364-5.
25. Lazic Z, Gajovic O, Tanaskovic I, et al. GOLD Stage Impact on COPD Direct Medical Costs in Elderly. Health Behav & Pub Health 2012; 2 (3): 1-7.
26. Cupurdija V, Lazic Z, Jakovljevic M. Cost of illness of community-acquired pneumonia. Review of the literature and possible strategies in the Serbian health care setting. Farmeconomia: Health, economics and therapeutic pathways 2012; 13 (3): 133-9.
27. Malik NN. Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol 2009; 6 (9): 550-2.
28. Jakovljevic MB, Djordjevic V, Markovic V, et al. Cross-sectional survey on complementary and alternative medicine awareness among health care professionals and students using CHBQ questionnaire in a Balkan country. Chin J Integr Med 2013; 19 (9): 650-5.
29. Yamada T, Chia Ching C, Smith J. Health Disparities and Health Integration. Journal of Health Behavior and Public Health 2012; 2 (1): 21-37.
30. Yabroff R, Lamont E, Mariotto A. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008; 100: 630-41.
31. Tanneberger S, Pannuti F, Mirri R, et al. Home hospital for advanced stage cancer patients: costs and benefits. Z Arztl Fortbild Qualitatssich 1997; 91 (2): 117-23.
32. Penson DF, Schonfeld WH, Flanders SC, et al. Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CAPSURE database. Urology 2001; 57 (3): 499-503.
33. Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995; 87 (6): 417-26.
34. Verdecchia A, Baili P, Quaglia A, et al. Patient survival for all cancers combined as indicator of cancer control in Europe. Eur J Public Health 2008; 18 (5): 527-32.
35. Barton MB, Frommer M, Shafiq J. Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet Oncol 2006; 7 (7): 584-95. Erratum in: Lancet Oncol. 7(10), 797 (2006)
36. Van Loon J, Grutters J, Macbeth F. Evaluation of novel radiotherapy technologies: what evidence is needed to assess their clinical and cost effectiveness, and how should we get it? Lancet Oncol 2012; 13 (4): e169-77.
37. Barton MB, Gebski V, Manderson C, et al. Radiation therapy: are we getting value for money? Clin Oncol (R Coll Radiol) 1995; 7 (5): 287-92.
38. Jakovljevic M, Rankovic A, Rancic N, et al. Radiology Services Costs and Utilization Patterns estimates in Southeastern Europe - A Retrospective Analysis from Serbia. Value in Health Regional Issues CEEWAA 2013; 2: 218-25.
39. Viale PH, Grande C, Moore S. Efficacy and cost: avoiding undertreatment of chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 2012; 16 (4): e133-141.
40. Lyman GH, Kuderer NM. The economics of the colony- stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004; 50(2): 129-46.
41. Wild F. Increases in pharmaceutical expenditures of PHI by monoclonal antibodies. Versicherungsmedizin 2013; 65(2): 91-3.
42. Kalo Z, Landa K, Dolezal T, et al. Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries. Eur J Cancer Care (Engl) 2012; 21 (4): 442-9.
43. Shparyk IaV, Koval‘chuk IV, Bilyns‘kyĭ BT, et al. The pharmacoeconomics of testicular cancer in Ukraine. Lik Sprava 1999; (7-8): 177-81.
44. Zavras A, Andreopoulos N, Katsikeris N, et al. Oral cancer treatment costs in Greece and the effect of advanced disease. BMC Public Health 2002; 2: 12.
45. Cakir Edis E, Karlikaya C. The cost of lung cancer in Turkey. Tuberk Toraks 2007; 55 (1): 51-8.
46. Zweifel P. The Grossman model after 40 years. Eur J Health Econ 2012; 13 (6): 677-82.
47. World Health Organization. Available at: http://www.who. int/cancer/en/ (Accessed 30 August 2013)
48. Kim K, Hernlund E, Hernadi Z, et al. Treatment patterns, health care utilization, and costs of ovarian cancer in Central and Eastern Europe using a Delphi panel based on a retrospective chart review. Int J Gynecol Cancer 2013; 23 (5): 823-32.
49. Rankovic A, Rancic N, Jovanovic M, et al. Impact of imaging diagnostics on the budget-are we spending too much? Vojnosanit Pregl 2013; 70 (7): 709-11.
50. Witteveen PO, van Groenestijn MA, Blijham GH, et al. Use of resources and costs of palliative care with parenteral fluids and analgesics in the home setting for patients with end-stage cancer. Ann Oncol 1999; 10 (2): 161-5.
51. Puder KL, Wood LL, Sherrill A. Health economics with retrospective data: selection bias issues. J Int Med Res 1997; 25 (1): 45-51.
52. Zweifel P. The present state of health economics: a critique and an agenda for the future. Eur J Health Econ 2013; 14 (4): 569-71.
53. Gulacsi L. Future challenges for health economics and health technology assessment of biological drugs. Eur J Health Econ 2010; 11 (3): 235-8.
54. Allan GM, Lexchin J. Physician awareness of diagnostic and nondrug therapeutic costs: a systematic review. Int J Technol Assess Health Care 2008; 24 (2): 158-65.
55. Jakovljevic M, Vukovic M, Antunovic M, et al. Do policy measures impact cost consciousness of healthcare professionals ? Value in Health 2013; 16 (7): A542.
56. André N, Banavali S, Snihur Y, et al. Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol 2013; 14 (6): e239-48.
57. Strother RM, Rao KV, Gregory KM, et al. The oncology pharmacy in cancer care delivery in a resource-constrained setting in western Kenya. J Oncol Pharm Pract 2012; 18 (4): 406-16.